BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36103835)

  • 1. Human hepatocyte PNPLA3-148M exacerbates rapid non-alcoholic fatty liver disease development in chimeric mice.
    Kabbani M; Michailidis E; Steensels S; Fulmer CG; Luna JM; Le Pen J; Tardelli M; Razooky B; Ricardo-Lax I; Zou C; Zeck B; Stenzel AF; Quirk C; Foquet L; Ashbrook AW; Schneider WM; Belkaya S; Lalazar G; Liang Y; Pittman M; Devisscher L; Suemizu H; Theise ND; Chiriboga L; Cohen DE; Copenhaver R; Grompe M; Meuleman P; Ersoy BA; Rice CM; de Jong YP
    Cell Rep; 2022 Sep; 40(11):111321. PubMed ID: 36103835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans.
    Ericson E; Bergenholm L; Andréasson AC; Dix CI; Knöchel J; Hansson SF; Lee R; Schumi J; Antonsson M; Fjellström O; Nasr P; Liljeblad M; Carlsson B; Kechagias S; Lindén D; Ekstedt M
    Hepatol Commun; 2022 Oct; 6(10):2689-2701. PubMed ID: 35833455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice.
    Lindén D; Ahnmark A; Pingitore P; Ciociola E; Ahlstedt I; Andréasson AC; Sasidharan K; Madeyski-Bengtson K; Zurek M; Mancina RM; Lindblom A; Bjursell M; Böttcher G; Ståhlman M; Bohlooly-Y M; Haynes WG; Carlsson B; Graham M; Lee R; Murray S; Valenti L; Bhanot S; Åkerblad P; Romeo S
    Mol Metab; 2019 Apr; 22():49-61. PubMed ID: 30772256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term hypercaloric diet exacerbates metabolic liver disease in PNPLA3 I148M animals.
    Su H; Haque M; Becker S; Edlund K; Duda J; Wang Q; Reißing J; Marschall HU; Candels LS; Mohamed M; Sjöland W; Liao L; Drexler SA; Strowig T; Rahnenführer J; Hengstler JG; Hatting M; Trautwein C
    Liver Int; 2023 Aug; 43(8):1699-1713. PubMed ID: 37073116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PNPLA3 I148M and response to treatment for hepatic steatosis: A systematic review.
    Boeckmans J; Gatzios A; Schattenberg JM; Koek GH; Rodrigues RM; Vanhaecke T
    Liver Int; 2023 May; 43(5):975-988. PubMed ID: 36719059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PNPLA3 I148M Variant Influences Circulating Retinol in Adults with Nonalcoholic Fatty Liver Disease or Obesity.
    Mondul A; Mancina RM; Merlo A; Dongiovanni P; Rametta R; Montalcini T; Valenti L; Albanes D; Romeo S
    J Nutr; 2015 Aug; 145(8):1687-91. PubMed ID: 26136587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro.
    Pirazzi C; Adiels M; Burza MA; Mancina RM; Levin M; Ståhlman M; Taskinen MR; Orho-Melander M; Perman J; Pujia A; Andersson L; Maglio C; Montalcini T; Wiklund O; Borén J; Romeo S
    J Hepatol; 2012 Dec; 57(6):1276-82. PubMed ID: 22878467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four-Week Omega-3 Supplementation in Carriers of the Prosteatotic PNPLA3 p.I148M Genetic Variant: An Open-Label Study.
    Kuttner CS; Mancina R; Wagenpfeil G; Lammert F; Stokes CS
    Lifestyle Genom; 2019; 12(1-6):10-17. PubMed ID: 31454802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PNPLA3 I148M variant promotes lipid-induced hepatocyte secretion of CXC chemokines establishing a tumorigenic milieu.
    Nischalke HD; Lutz P; Bartok E; Krämer B; Langhans B; Frizler R; Berg T; Hampe J; Buch S; Datz C; Stickel F; Hartmann G; Strassburg CP; Nattermann J; Spengler U
    J Mol Med (Berl); 2019 Nov; 97(11):1589-1600. PubMed ID: 31637480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.
    Donati B; Motta BM; Pingitore P; Meroni M; Pietrelli A; Alisi A; Petta S; Xing C; Dongiovanni P; del Menico B; Rametta R; Mancina RM; Badiali S; Fracanzani AL; Craxì A; Fargion S; Nobili V; Romeo S; Valenti L
    Hepatology; 2016 Mar; 63(3):787-98. PubMed ID: 26605757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and Targeting of the Signaling Controls of
    Schwartz BE; Rajagopal V; Smith C; Cohick E; Whissell G; Gamboa M; Pai R; Sigova A; Grossman I; Bumcrot D; Sasidharan K; Romeo S; Sehgal A; Pingitore P
    Cells; 2020 Oct; 9(10):. PubMed ID: 33036387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease.
    Park J; Zhao Y; Zhang F; Zhang S; Kwong AC; Zhang Y; Hoffmann HH; Bushweller L; Wu X; Ashbrook AW; Stefanovic B; Chen S; Branch AD; Mason CE; Jung JU; Rice CM; Wu X
    J Hepatol; 2023 Jan; 78(1):45-56. PubMed ID: 36049612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of different genotypes of PNPLA3 I148M on hepatocyte proliferation].
    Yan XM; Yuan SH; Xu X; Ai HY; Liang H
    Zhonghua Yi Xue Za Zhi; 2018 Sep; 98(34):2754-2759. PubMed ID: 30220174
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of Steatohepatitis.
    Banini BA; Kumar DP; Cazanave S; Seneshaw M; Mirshahi F; Santhekadur PK; Wang L; Guan HP; Oseini AM; Alonso C; Bedossa P; Koduru SV; Min HK; Sanyal AJ
    Hepatology; 2021 Apr; 73(4):1290-1306. PubMed ID: 33131062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.
    Scorletti E; West AL; Bhatia L; Hoile SP; McCormick KG; Burdge GC; Lillycrop KA; Clough GF; Calder PC; Byrne CD
    J Hepatol; 2015 Dec; 63(6):1476-83. PubMed ID: 26272871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PNPLA3 I148M is involved in the variability in anti-NAFLD response to exenatide.
    Chen Y; Yan X; Xu X; Yuan S; Xu F; Liang H
    Endocrine; 2020 Dec; 70(3):517-525. PubMed ID: 32862405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of
    Liu M; Park S
    Nutrients; 2024 Apr; 16(8):. PubMed ID: 38674929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C.
    Zampino R; Coppola N; Cirillo G; Boemio A; Pisaturo M; Marrone A; Macera M; Sagnelli E; Perrone L; Adinolfi LE; Miraglia del Giudice E
    J Viral Hepat; 2013 Aug; 20(8):517-23. PubMed ID: 23808989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PNPLA3 I148M polymorphism and progressive liver disease.
    Dongiovanni P; Donati B; Fares R; Lombardi R; Mancina RM; Romeo S; Valenti L
    World J Gastroenterol; 2013 Nov; 19(41):6969-78. PubMed ID: 24222941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population.
    Unalp-Arida A; Ruhl CE
    Hepatology; 2020 Mar; 71(3):820-834. PubMed ID: 31705824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.